Trenton, NJ – A federal judge has denied consumers’ request to reconsider part of a ruling that trimmed their sweeping challenge to the alleged insulin pricing scheme led by Novo Nordisk, Sanofi, and Eli Lilly.

Motion for reconsideration denied

U.S. District Judge Brian R. Martinotti on Wednesday refused to alter his earlier order that granted in part and denied in part the drugmakers’ motion to dismiss. Plaintiffs, who filed a Fourth Amended Complaint in March 2024, had asked the court to reinstate certain claims that were dismissed in that ruling.

Case alleges artificial list price hikes

The litigation, which began in 2017, accuses the three manufacturers of conspiring to inflate list prices for insulin while secretly rebating portions of those prices to pharmacy benefit managers (PB

See Full Page